New combo therapy targets hard-to-treat breast cancer

NCT ID NCT05095207

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Apr 14, 2026 · Last updated May 08, 2026 · Updated 5 times

Summary

This study tests a combination of two drugs, abemaciclib and bicalutamide, for people with a specific type of advanced breast cancer that has spread (metastatic). The cancer must test positive for androgen receptors and negative for HER2. The goal is to find the best dose and see how well the treatment controls the disease. About 42 adults are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dubin breast Center
RECRUITING

New York, New York, 10029, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Mount Sinai - West
RECRUITING

New York, New York, 10019, United States
Mount Sinai Beth Israel
RECRUITING

New York, New York, 10003, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER METASTASIS